Financial Overview: As of June 30, 2025, Autolus Therapeutics reported cash and equivalents totaling $454.3 million, a decrease from $588.0 million at the end of 2024, primarily due to operating cash outflows and a delayed R&D tax credit receipt of approximately $21.7 million from the UK HMRC.
Company Outlook: Despite the decrease in cash reserves, Autolus believes it is well-capitalized to support the launch of its product obe-cel for r/r B-ALL and to gather data from ongoing clinical trials.
AUTL
$1.6+Infinity%1D
Analyst Views on AUTL
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.620
Low
5.00
Averages
7.68
High
10.00
Current: 1.620
Low
5.00
Averages
7.68
High
10.00
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Needham
Gil Blum
Price Target
$10
2025-04-10
Reiterates
Strong Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist Securities
Asthika Goonewardene
Price Target
$11 → $10
2025-04-01
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Wells Fargo
Yanan Zhu
Price Target
$8 → $6
2025-03-21
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-01-13
Reason
Needham
Gil Blum
Price Target
$10
2025-01-13
Reiterates
Strong Buy
Reason
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
